NasdaqGM:OCSPharmaceuticals
Oculis Resets After OCS-01 Setback And Refocuses On Late-Stage Pipeline
Oculis Holding reported that its two Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema did not meet primary or key secondary vision endpoints.
The company will not pursue an FDA filing for OCS-01 in this indication and will instead focus resources on other late-stage ophthalmic drug candidates.
Shares of NasdaqGM:OCS most recently closed at $14.51.
For investors watching NasdaqGM:OCS, the update on OCS-01 represents a major reset for Oculis Holding, since this was a key late-stage...